Home / Health / FDA Greenlights New Myasthenia Gravis Treatment

FDA Greenlights New Myasthenia Gravis Treatment

Summary

  • FDA approved a new drug for generalized myasthenia gravis.
  • The drug treats adults with specific anti-acetylcholine receptor antibodies.
  • Regeneron Pharmaceuticals developed the newly approved medication.

On Thursday, November 16, 2026, the US Food and Drug Administration announced its approval of a new drug developed by Regeneron Pharmaceuticals. This medication is indicated for adults diagnosed with generalized myasthenia gravis.

The treatment is specifically for those individuals who test positive for anti-acetylcholine receptor antibodies. This targeted approach aims to provide effective therapy for a defined patient population within the broader myasthenia gravis community.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.

Read more news on

Property Code: 5571